Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) is an enzyme encoded by the B3GNT3 gene in humans. It is a type II transmembrane glycosyltransferase that catalyzes the transfer of N-acetylglucosamine (GlcNAc) residues via a beta-1,3 linkage to specific substrates, such as lacto-N-tetraose and lacto-N-neotetraose, leading to the biosynthesis of poly-N-acetyllactosamine chains. B3GNT3 plays a crucial role in the generation of sialyl Lewis a/x structures, which are important for L-selectin ligand biosynthesis, lymphocyte homing, and trafficking. Its activity also contributes to fundamental pathways in glycoprotein modification and immune cell behavior.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3).